Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Acrivon Therapeutics, Inc. - Common Stock (NQ:ACRV)

1.630 -0.120 (-6.86%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acrivon Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost ↗
Acrivon Therapeutics stock is up on Tuesday with heavy trading of ACRV shares alongside $130 million in new funding today. 
Via InvestorPlace
News headline image
Acrivon Therapeutics Stock Is Soaring Tuesday: What's Going On? ↗
Acrivon Therapeutics has entered into a securities purchase agreement to issue and sell 8.235 million shares of its common stock at a price of $8.50 per share, as well as pre-funded warrants to... 
Via Benzinga
News headline image
Dow Gains Over 50 Points; Neogen Posts Downbeat Earnings ↗
U.S. stocks traded higher this morning, with the Dow Jones index gaining over 50 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.20% to 38,972.32 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Acrivon Therapeutics Announces $130 Million Private Placement Financing
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
ACRV Stock Earnings: Acrivon Therapeutics Misses EPS for Q4 2023 ↗
ACRV stock results show that Acrivon Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Analyst Ratings for Acrivon Therapeutics ↗
 
Via Benzinga
News headline image
Recap: Acrivon Therapeutics Q3 Earnings ↗
 
Via Benzinga
News headline image
Analyst Expectations for Acrivon Therapeutics's Future ↗
 
Via Benzinga
News headline image
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies
From Acrivon Therapeutics, Inc
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.